Psyched Wellness (CSE:PSYC, FRA:5U9, OTCQB:PSYCF) Ltd CEO Jeff Stevens tells Proactive it has initiated the first steps towards a clinical sleep study for a structure/function claim for its proprietary extract (AME-1) from Amanita Muscaria mushrooms.
The company said the aim of the study is to carry out an assessment of a novel sleep-enhancing food supplement for self-declared insomniacs based on both subjective and objective sleep measures, including residual effects.
What's more, the group has been included in the new AdvisorShares Psychedelics Exchange Traded Fund (ETF).